



# LESS FEAR, **MORE HOPE**

We are **ONE**.  
We, **TOGETHER**, are Sigilon.

At Sigilon, our goal is to liberate patients from chronic diseases with our Shielded Living Therapeutics™ platform. Our engineered cell therapies are designed to restore cell function in a person living with a chronic disease or disorder such as rare blood, lysosomal storage or endocrine disorders. We care deeply about patients and caregivers and we are working to create therapies with the potential to deliver functional cures. We envision a future with less fear of “what ifs.” We, together, can deliver on hope.

We  
care

We  
pioneer

We  
act

We  
trust

We  
create

Patients and caregivers are at the center of our core values.



Here is Team Sigilon at the NEHA Unite for Bleeding Disorders Walk in 2019

**sigilon**  
therapeutics™


©2020 Sigilon Therapeutics, Inc.

# A NOVEL APPROACH

We have the courage to pioneer a new class of medicines that could potentially deliver functional cures for patients living with chronic diseases such as rare blood disorders, lysosomal storage disorders and type 1 diabetes. We are harnessing the body's most powerful machine - the cell - to create a new category of medicine: Shielded Living Therapeutics™.


## Shielded Living Therapeutics™ platform

### Engineer



Our investigational therapies start with human cells engineered to produce clotting factors, hormones, enzymes or other proteins that are missing or deficient.

### Shield



We then put the cells into tiny spheres. These special spheres do two things:

1. Shield the cells from your body's immune system, preventing them from being attacked.
2. Allow the inflow of nutrients and the outflow of a specific therapy

**Fast Fact:** 20,000 to 40,000 cells fit into one sphere. Each sphere is 1.5 mm in diameter.


### Prepare



Here's what a potential dose could look like.


For purposes of this visualization, we have colored the spheres blue, but in reality, they are clear.

### Place



For our clinical studies, a doctor will place the spheres into your abdomen via a minimally invasive procedure. Protected by the shielded spheres, the cells are designed to live where they are placed, producing the specific protein you need, which will then circulate throughout the body.

### Produce



The cells are designed to produce sustained, long-lasting levels of the therapeutic protein. This technology allows us to re-dose if necessary.

## Our Therapeutic Focus

We have focused our research on three therapeutic areas where we believe there's a high need for innovative treatments. We expect to initiate our first clinical trial in Hemophilia A in 2020. We are also working hard to bring other important investigational programs to the clinic.

### Rare Blood Disorders

- Hemophilia A
- Hemophilia B
- Factor VII deficiency

### Lysosomal Storage Disorders

- Fabry disease
- Mucopolysaccharidosis I (MPS 1)

### Endocrine & Other Chronic Disorders

- Type 1 diabetes
- Hypoparathyroidism
- Eye diseases

To learn more, please visit us at: [sigilon.com](http://sigilon.com)

Or reach out to us at: [patients@sigilon.com](mailto:patients@sigilon.com)

**sigilon**  
therapeutics™

Follow us on social media:

